BioStem Technologies CEO exercises 250K share options
Additional reported equity holdings included three option positions with exercise prices of $5.50 or $10.05, convertible preferred shares, and restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioStem Technologies, Inc. Chief Executive Officer Jason Matuszewski exercised options to acquire 250,000 common shares at a $2.00-per-share exercise price on October 7, 2026. The options were fully vested and exercisable. After the exercise, he directly held 1,553,551 common shares; the reported balance corrects a prior one-share overstatement from an administrative error in reporting an earlier restricted stock unit vesting.
Insights
Analyzing...
Insider Trade Summary
250,000 shares exercised/converted
Exercise
9 txns
Insider
Matuszewski Jason
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Options (Right to Buy) F5 | 250,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 250,000 | $2.00 | $500K |
| holding | Series A-1 Convertible Preferred Shares F2, F3, F4 | -- | -- | -- |
| holding | Options (Right to Buy) F6 | -- | -- | -- |
| holding | Options (Right to Buy) F7 | -- | -- | -- |
| holding | Options (Right to Buy) F8 | -- | -- | -- |
| holding | Restricted Stock Units F9, F10 | -- | -- | -- |
| holding | Restricted Stock Units F9, F11, F1 | -- | -- | -- |
| holding | Restricted Stock Units F9, F12 | -- | -- | -- |
Holdings After Transaction:
Options (Right to Buy) — 2,679,763 contracts for 679,763 underlying shares (Direct);
Common Stock — 1,553,551 shares (Direct);
Series A-1 Convertible Preferred Shares — 100 contracts (Direct);
Restricted Stock Units — 497,411 contracts (Direct)
Footnotes (12)
- F1. The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error.
- F2. The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.
- F3. The Series A-1 Convertible Preferred Shares have no expiration date.
- F4. Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.
- F5. These options are fully vested and exercisable.
- F6. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F7. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F8. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F9. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F10. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
- F11. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F12. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
Options exercised: 250,000 shares
Exercise price: $2.00 per share
Common shares acquired: 250,000 shares
+4 more
7 metrics
Options exercised
250,000 shares
Exercise reported October 7, 2026
Exercise price
$2.00 per share
Options exercised October 7, 2026
Common shares acquired
250,000 shares
October 7, 2026
Common shares held after exercise
1,553,551 shares
Direct holdings following the October 7, 2026 transaction
Common shares underlying options
198,807 shares
$10.05 exercise price; expiration March 17, 2035
Common shares underlying options
40,427 shares
$10.05 exercise price; expiration October 13, 2035
Common shares underlying options
440,529 shares
$5.50 exercise price; expiration February 11, 2036
Key Terms
Options (Right to Buy), Series A-1 Convertible Preferred Shares, Restricted Stock Units, fully vested and exercisable
4 terms
Options (Right to Buy) financial
"These options are fully vested and exercisable."
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
fully vested and exercisable financial
"These options are fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What other options did the BSEM CEO report holding?
The reported direct option positions covered 198,807 common shares at a $10.05 exercise price, expiring March 17, 2035; 40,427 shares at $10.05, expiring October 13, 2035; and 440,529 shares at $5.50, expiring February 11, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
